In This Section

chorny [at]
Location - People View
Room 702G

3615 Civic Center Blvd
Philadelphia, PA 19104
United States

Michael Chorny, PhD
Michael Chorny

Dr. Chorny's research program focuses on nanomedicines as well as drug, cell, and gene delivery systems for treating proliferative disease. His current research specifically focuses on the use of nanoparticle-mediated delivery to solid tumors and site-specific delivery for cardiovascular disease.



Subscribe to be notified of changes or updates to this page.

1 + 4 =
Solve this simple math problem and enter the result. E.g. for 1+3, enter 4.


Dr. Chorny's research focuses on the development of new, targeted delivery approaches for treating proliferative diseases. Over the past several years he has worked on the design of different formulation strategies for targeted delivery of small-molecular antiproliferative agents, biotherapeutics, and cells.

Over the past several years, Dr. Chorny and his colleagues at Children’s Hospital of Philadelphia and University of Pennsylvania have developed new approaches for producing biodegradable nanocarriers and for examining their drug release behavior, disassembly patterns, intracellular fate, biodistribution, as well as therapeutic and adverse effects.

One of Dr. Chorny's current research projects involves understanding how nanoparticle (NP)-mediated delivery to solid tumors can be controlled and improved by using rationally designed, in situ activatable co-drugs. New NP/co-drug formulations developed using this knowledge may lead to a better therapy for aggressive cancers that resist conventional treatments.

In addition, he has an active project on cardiovascular disease that investigates site-specific schemes designed to increase arterial uptake and extend the local presence of a cell type-selective prohealing agent (estradiol). The goal of the research is to develop a flexible and safer alternative to existing approaches for treating post-angioplasty restenosis.

The approach being studied by Dr. Chorny involves formulating in situ activatable macromolecular prodrugs to achieve controlled drug release and stable anchorage within the injured arterial wall for inhibiting intimal hyperplasia and stimulating endothelium growth in stented arteries.

Education and Training

BPharm, The Hebrew University of Jerusalem (Pharmaceutical Sciences), 1996

MS, The Hebrew University of Jerusalem (Biomedical Nanotechnology), 1997

PhD, The Hebrew University of Jerusalem (Nanocarriers for Site Specific Vascular Therapy), 2004

Fellowship, Children's Hospital of Philadelphia (Nanocarrier-mediated Targeted Delivery), 2008

Titles and Academic Titles


Research Associate Professor of Pediatrics

Professional Memberships

American Heart Association, 2008-

American Society of Gene and Cell Therapy, 2009-

Controlled Release Society, 2010-

Professional Awards

Outstanding Presentation in Basic Research, Children's Hospital of Philadelphia, 2006

New Investigator Award from the Ethel Brown Foerderer Fund for Excellence, 2009

Certificate of Research Excellence from the American Heart Association, 2011


Publication Highlights

Links of Interest